<DOC>
	<DOCNO>NCT00329056</DOCNO>
	<brief_summary>In Parkinson 's Disease , mitochondrial membrane cell produce dopamine become damage oxidant , lead death cell progressive tremor , slowness movement loss neuron substantia nigra ( part brain involved movement ) . Mitoquinone target reach membrane mitochondrion provide protection damaging oxidant . There treatment currently available slow progression PD trial help advance development unique disease modify drug . This trial enroll 120 participant untreated early onset PD . Participants randomize receive 1 3 treatment : 40 mg MitoQ tablet , 80 mg MitoQ tablets placebo . The researcher , participant sponsor blind treatment allocation . Participants assess 1 , 2 , 3 , 6 , 9 , 12 month treatment 28 day last dose . The effectiveness trial drug measure via Unified Parkinson 's Disease Rating Scale ( UPDRS ) . The safety trial drug monitor via regular participant examination , blood test , ECG collect information adverse event .</brief_summary>
	<brief_title>A Trial MitoQ Treatment People With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>1 . Informed consent 2 . 30 yrs old 3 . Diagnosis PD ( 2 bradykinesia ; rest tremor , rigidity ) 4 . Adequate contraceptive measure ( female ) 1 . Malignancy within last 2 year 2 . Pregnancy &amp; breastfeed 3 . Treatment antiPD drug within 30 day enrolment 4 . Prior treatment antiPD medication exceed 42 day total 5 . Medicationinduced PD/PD idiopathic origin 6 . CoQ10/idebenone dose 300mg/day high within 120 day , &gt; 25mg/day within 7 day enrolment 7 . Methylphenidate HCl , neuroleptic , reserpine , amphetamine , selegeline MAOIs within 6 month enrolment 8 . CNS medication unstable dos within 60 day enrolment 9 . Dietary supplement &gt; 5 x RDI 10 . Hypersensitivity CoQ10 , idebenone component study drug 11 . Unable swallow 12 . Diseases feature PD 13 . Seizure ( ) within 12 month prior enrolment 14 . UPDRS tremor score 4 15 . Hamilton Depression Rating Scale score &gt; 10 16 . History stroke 17 . Requirement dopaminergic drug 18 . Modified Hoehn &amp; Yahr score &gt; 2.5 19 . History brain surgery Parkinson 's disease 20 . History structural brain disease / congenital brain abnormality 21 . History ECT 22 . Any clinically significant medical psychiatric condition lab abnormality 23 . Enrolment pharmacological study within 30 day enrolment</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>MitoQ</keyword>
	<keyword>UPDRS</keyword>
</DOC>